Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Initiative to eliminate cervical cancer in North Carolina

Patricia Gregory of Cary was only 24 years old when she was diagnosed with cervical cancer. Now a mother of an 11-year-old daughter, she considers herself blessed to have a child, as cervical cancer can make women unable to bear children.

21 Jan 2011

Offensive protein generated by HPV handicaps defensive protein made by the human body

An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

12 Jan 2011

Male circumcision helps reduce rates of HPV transmission to women, study finds

"Among HIV-negative sexual partners, male circumcision helps prevent the transmission of human papillomavirus [HPV] from men to women," according to a study published online Thursday in the Lancet, HealthDay News/Bloomberg Businessweek reports.

10 Jan 2011

Get examined during National Cervical Cancer Awareness Month

Cervical cancer is the second leading cause of cancer in women worldwide, yet it is almost always preventable – with the Pap test, the HPV test and the HPV vaccine. That's what the Pearl of Wisdom Campaign to Prevent Cervical Cancer wants women to know – and share with their mothers, daughters, sisters and friends.

7 Jan 2011

VEREGEN Ointment added as new therapeutic option in 2010 CDC STD Treatment Guidelines

PharmaDerm, a division of Nycomed US Inc., announced today that VEREGEN (sinecatechins) Ointment, 15%, a topical medication for the treatment of external genital and perianal warts, has been added as a new therapeutic option in the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.

6 Jan 2011

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Men are more willing to receive human papillomavirus vaccine when they learn the vaccine can prevent cancer, according to a recent University of North Carolina at Chapel Hill study.

5 Jan 2011

Mothers can play a key role in convincing college-aged women to receive HPV vaccine

Even after young women reach adulthood, their mothers can play a key role in convincing them to receive the human papillomavirus vaccine, new research suggests.

3 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA approves Gardasil for prevention of anal cancer

The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

23 Dec 2010

Program reduces cervical cancer deaths among HIV-infected women in Zambia

A new study undertaken in Zambia shows that, using setting-appropriate human resources and technology, morbidity and mortality from cervical cancer among HIV-infected women can be reduced. The study’s lead author is Dr Groesbeck Parham, Professor of Gynecologic Oncology and Infectious Diseases, University of Alabama at Birmingham, and Director of the Centre for Infectious Disease Research in Zambia’s Cervical Cancer Prevention Program. The research was published in the December issue of HIV Therapy.

14 Dec 2010

Indiana University to join multi-state program focused on cervical cancer prevention

Indiana will join a multi-state program focused on cervical cancer prevention thanks to an unrestricted gift from GlaxoSmithKline Pharmaceuticals to the Indiana University School of Medicine, in partnership with the Kristen Forbes EVE Foundation.

3 Dec 2010

FDA accepts to file PMA application for LightTouch Cervical Scanner

Guided Therapeutics, Inc. announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company's premarket approval application (PMA) for the LightTouch Cervical Scanner, for patients at risk for cervical cancer, is suitable for filing.

3 Dec 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Gen-Probe submits PMA to FDA for APTIMA HPV assay to detect cervical cancer

Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.

30 Nov 2010

SaneVax Team congratulates Senator for examining NCI ethical questions

In a letter addressed to U.S. Senator Charles Grassley, the SaneVax Team congratulated the senator on his recent efforts to examine ethical questions raised by National Cancer Institute (NCI) employees accepting extensive travel sponsored by private companies and identified two senior NCI scientists who knowingly promote unreliable human papillomavirus (HPV) tests for patient care, and the development/monitoring of genotype-specific HPV vaccines to promote an unproven virology-based cervical cancer prevention business agenda.

29 Nov 2010

Is the decade long flirtation with vaccines over?

In light of increasing competition, saturation of key vaccine sectors and a lack of innovative late-stage vaccine candidates, maintaining the strong growth of the last decade will be a major challenge for the vaccines industry suggests independent market analyst, Datamonitor.

22 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

FIP's PSWC and AAPS Annual Meeting to highlight targeted inhalable dry powder HPV vaccine

New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Never-smokers have better chance of surviving head and neck cancer

Patients with head and neck cancer who have never smoked have much better survival rates after radiation therapy than patients with a history of smoking, new research from UC Davis Cancer Center has found.

17 Nov 2010

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Initiative to eliminate cervical cancer in North Carolina

Offensive protein generated by HPV handicaps defensive protein made by the human body

Male circumcision helps reduce rates of HPV transmission to women, study finds

Get examined during National Cervical Cancer Awareness Month

VEREGEN Ointment added as new therapeutic option in 2010 CDC STD Treatment Guidelines

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Mothers can play a key role in convincing college-aged women to receive HPV vaccine

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

FDA approves Gardasil for prevention of anal cancer

Program reduces cervical cancer deaths among HIV-infected women in Zambia

Indiana University to join multi-state program focused on cervical cancer prevention

FDA accepts to file PMA application for LightTouch Cervical Scanner

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Gen-Probe submits PMA to FDA for APTIMA HPV assay to detect cervical cancer

SaneVax Team congratulates Senator for examining NCI ethical questions

Is the decade long flirtation with vaccines over?

CDC data: Adults remain unvaccinated against preventable infectious illnesses

FIP's PSWC and AAPS Annual Meeting to highlight targeted inhalable dry powder HPV vaccine

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Never-smokers have better chance of surviving head and neck cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in